Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04764110 · ClinicalTrials.gov registry record · NA
Short-term Impact of Cyplexinol® on Self-reported Joint Pain
A NA study, sponsored by University of Memphis.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT04764110 is a NA study that has completed, run by University of Memphis. The registered enrollment target is 18 participants.
The verdict
NCT04764110, a NA study, has completed, sponsored by University of Memphis.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
In this study, the impact of 900 mg Cyplexinol® taken daily on joint pain over a period of 15 days in comparison with a placebo will be determined using a cross-over double blind design with a 13 day wash out period. In addition, we will measure cytokine production and related variables during the two hour after subjects ingest a single dosage of Cyplexinol® or placebo on days 1 and 15.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Cyplexinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2022-01-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04764110
The ClinicalTrials.gov registry entry for NCT04764110 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Memphis, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04764110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04764110 about?
NCT04764110 is a clinical study titled "Short-term Impact of Cyplexinol® on Self-reported Joint Pain". In this study, the impact of 900 mg Cyplexinol® taken daily on joint pain over a period of 15 days in comparison with a placebo will be determined using a cross-over double blind design with a 13 day wash out period. In addition, we will measure cytokine production and related variables during the t...
What is the current status of trial NCT04764110?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2021-03-17. Estimated completion is 2022-01-28.
What interventions are being tested in trial NCT04764110?
The interventions under investigation include: Placebo (OTHER), Cyplexinol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04764110?
This trial is sponsored by University of Memphis, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.